LLY

995.89

+0.83%↑

JNJ

205.37

+2.21%↑

ABBV

225.66

+0.44%↑

UNH

328.11

+1.49%↑

AZN

91.33

+1.39%↑

LLY

995.89

+0.83%↑

JNJ

205.37

+2.21%↑

ABBV

225.66

+0.44%↑

UNH

328.11

+1.49%↑

AZN

91.33

+1.39%↑

LLY

995.89

+0.83%↑

JNJ

205.37

+2.21%↑

ABBV

225.66

+0.44%↑

UNH

328.11

+1.49%↑

AZN

91.33

+1.39%↑

LLY

995.89

+0.83%↑

JNJ

205.37

+2.21%↑

ABBV

225.66

+0.44%↑

UNH

328.11

+1.49%↑

AZN

91.33

+1.39%↑

LLY

995.89

+0.83%↑

JNJ

205.37

+2.21%↑

ABBV

225.66

+0.44%↑

UNH

328.11

+1.49%↑

AZN

91.33

+1.39%↑

Home・Akciju saraksts・TG Therapeutics Inc

TG Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

30.7 0.99

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.53

Max

30.73

Galvenie mērījumi
By Trading Economics
Ienākumi	363M 391M
Pārdošana	21M 162M
P/E Sektora vidējais	11.13 80.03
Peļņas marža	241.727
Darbinieki	374
EBITDA	-4.9M 33M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+47.88% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-451M 4.9B
Iepriekšējā atvēršanas cena	29.71
Iepriekšējā slēgšanas cena	30.7

Ziņu noskaņojums

By Acuity

23%

77%

51 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

N/A / 34.86 Atbalsts un pretestība

TG Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. dec. 22:13 UTC

Peļņas

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025. g. 9. dec. 21:40 UTC

Peļņas

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025. g. 9. dec. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025. g. 9. dec. 16:57 UTC

Galvenie tirgus virzītāji

Clear Secure Rises on Medicare Identity Verification Contract

2025. g. 9. dec. 23:46 UTC

Tirgus saruna

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025. g. 9. dec. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings Stake in Lenovo Now at 32.34%

2025. g. 9. dec. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025. g. 9. dec. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025. g. 9. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025. g. 9. dec. 22:42 UTC

Peļņas

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 21:48 UTC

Tirgus saruna

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025. g. 9. dec. 20:28 UTC

Tirgus saruna

Oil Futures Decline for Second Straight Session -- Market Talk

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Reports Voting Results From Special Meeting of Hldrs

2025. g. 9. dec. 20:26 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025. g. 9. dec. 20:21 UTC

Tirgus saruna

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025. g. 9. dec. 19:52 UTC

Peļņas

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025. g. 9. dec. 19:17 UTC

Peļņas

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025. g. 9. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. dec. 17:11 UTC

Peļņas

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

TG Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

47.88% augšup

Prognoze 12 mēnešiem

Vidējais 45 USD 47.88%

Augstākais 60 USD

Zemākais 11 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi TG Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam TG Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 34.86Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

Noskaņojums

By Acuity

51 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.